Johannes Nagelschmitz und Bayer - Info zur Person

(1 - 17 von 17

)

搜索X-MOL

newsletter.x-mol.com

... Johannes Nagelschmitz 1 , Stephanie Loewen 3. Affiliation. Bayer AG, Research & Development, …s, Translational MedicineWuppertal ...

LinkedIn: Johannes Nagelschmitz - Bayer …sLinkedIn

Johannes Nagelschmitz. Director Clinical Pharmacology bei Bayer …s. Bayer …s. Nordrhein-Westfalen, Deutschland.

LinkedIn: Johannes H. Dr. Nagelschmitz | LinkedIn

Johannes Nagelschmitz. Project Leader Clinical Pharmacology bei Bayer …s. Johannes Büttner. Physician at University Hospital Tübingen. nasim …

Bio… Characteristics of Nifurtimox Tablets for ...Wiley

accp1.onlinelibrary.wiley.com

von H Stass · · Zitiert von: 13 — ... Johannes Nagelschmitz,. Johannes Nagelschmitz. Bayer AG, Wuppertal, Germany. Search for more papers by this author · Boris Weimann,. Boris ... von H Stass · · Zitiert von: 13 — ... Johannes Nagelschmitz,. Johannes Nagelschmitz. Bayer AG, Wuppertal, Germany. Search for more papers by this author · Boris Weimann,. Boris ...

HNE chemical probe - BAY-678Bayer

www.bayer.com

— Johannes Nagelschmitz. Julia Freundlieb. Karl-Heinz Schlemmer. Katja Zimmermann. Kevin Nash. Klemens …ig. Lars Bärfacker. Leila Telan. Martin ...

Martin Blunck's research works | Bayer HealthCare ...ResearchGate

www.researchgate.net

Johannes Nagelschmitz · Martin Blunck · Jörn Krätzschmar · Mathias Ludwig · [object Object]. Thomas Hohlfeld · View full-text ... This conclusion also is ... Johannes Nagelschmitz · Martin Blunck · Jörn Krätzschmar · Mathias Ludwig · [object Object]. Thomas Hohlfeld · View full-text ... This conclusion also is ...

Results from Drug-Drug Interaction Studies In Vitro and In ...National Institutes of Health (NIH) (.gov)

pubmed.ncbi.nlm.nih.gov

von R Heinig · · Zitiert von: 20 — Authors. Roland Heinig , Michael Gerisch , Michaela Bairlein , Johannes Nagelschmitz , Stephanie Loewen. Affiliations. 1 Bayer AG, Research and ... von R Heinig · · Zitiert von: 20 — Authors. Roland Heinig , Michael Gerisch , Michaela Bairlein , Johannes Nagelschmitz , Stephanie Loewen. Affiliations. 1 Bayer AG, Research and ...

Pharmacokinetics of the Novel, Selective, Non-steroidal ...OUCI

ouci.dntb.gov.ua

... Johannes Nagelschmitz, Stephanie Loewen. Funder Bayer. List of references. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and ...

Johannes Nagelschmitz email address & phone number | Bayer ...RocketReach

rocketreach.co

Johannes Nagelschmitz, based in North Rhine-Westphalia, Germany, is currently a Project Leader Clinical Pharmacology at Bayer …s. Johannes Nagelschmitz, based in North Rhine-Westphalia, Germany, is currently a Project Leader Clinical Pharmacology at Bayer …s.

A Phase I, Randomized, Dose-Escalation StudyClinical The…utics

von H Stass · · Zitiert von: 65 — ; Johannes Nagelschmitz, PhD, MD. 1. ;. Claudia Rolinck-Werninghaus, MD. 3. ; and Doris Staab, MD Bayer Pharma AG, Global Drug Discovery, Development ... von H Stass · · Zitiert von: 65 — ; Johannes Nagelschmitz, PhD, MD. 1. ;. Claudia Rolinck-Werninghaus, MD. 3. ; and Doris Staab, MD Bayer Pharma AG, Global Drug Discovery, Development ...

Inhalation of a dry powder …floxacin formulation in ...National Institutes of Health (NIH) (.gov)

pubmed.ncbi.nlm.nih.gov

von H Stass · · Zitiert von: 105 — Johannes Nagelschmitz, Stefan Willmann, Heinz Delesen, Abhishek Gupta, Sybille Baumann. Affiliation. 1 Bayer Pharma AG, Clinical Pharmacology, Bldg 470, Room ... von H Stass · · Zitiert von: 105 — Johannes Nagelschmitz, Stefan Willmann, Heinz Delesen, Abhishek Gupta, Sybille Baumann. Affiliation. 1 Bayer Pharma AG, Clinical Pharmacology, Bldg 470, Room ...

搜索X-Mol

www.x-mol.com

Roland Heinig 1 , Johannes Nagelschmitz 1 , Stephanie Loewen 2. Affiliation. Bayer AG, Research & Development, …s, Translational Medicine, Roland Heinig 1 , Johannes Nagelschmitz 1 , Stephanie Loewen 2. Affiliation. Bayer AG, Research & Development, …s, Translational Medicine,